Stocks in play: Defence Therapeutics Inc.

Just completed a pre-clinical study using its intranasal formulation of AccuTOXTM in the context of animals with pre-established lung cancer. The study shows that AccuTOXTM administration as a combination therapy with the immune-checkpoint inhibitor anti-PD1 reduces dramatically the level of lung nodules compared to control non-treated or anti-PD1-treated animals. This 50% reduction of cancer nodules on animals with pre-established lung tumors was achieved in a treatment plan of only 6 administrated doses over 2 weeks with the AccuTOXTM anti-PD1 combination. Defence Therapeutics Inc. shares C.DTC are trading unchanged at $2.71.

Read:

• Addressing the USA’s 200 to 1 Security Protection Gap is a Serious Concern for Tech Companies

• Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector

• Biotech Sector to Unveil New Data and Developments at 2022 SABCS in San Antonio

• Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

• New Biotech Sector Drug Combinations Target a Drop in Pancreatic Cancer Mortality Rates